medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 2

<< Back Next >>

Ann Hepatol 2018; 17 (2)

Recent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs

Meunier L, Larrey D

Language: English
References: 20
Page: 187-191
PDF size: 126.88 Kb.


ABSTRACT

Non-steroidal-anti-inflammatory drugs (NSAIDs) make a heterogenous pharmaco-therapeutic class of drugs among the most used drugs worldwide with various indications, modes of administration and increasing automedication. NSAIDs can cause acute liver injury with variable severity. The recent identification of genetic markers might facilitate the diagnosis and the prediction of hepatotoxicity risk.


REFERENCES

  1. Lewis JH, Stine JG. Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists. In: Drug-induced liver disease. Eds. Kaplowitz N, DeLeve DL. Third Ed. Amsterdam, Boston, London, New-York, Oxford, Paris: 2013; pp. 369- 401.

  2. Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003; 12: 315-26.

  3. Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci 2016; 17: 224-31.

  4. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.

  5. Gulmez SE, Larrey D, Pageaux G-P, Lignot S, Lassalle R, Jové J, Gatta A, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013; 36: 135-44.

  6. Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, Russo MW, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int Off J Int Assoc Study Liver 2016; 36: 603?9.

  7. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis 2013; 17: 643-56.

  8. LiverTox: http://livertox.nlm.nih.gov.

  9. Larrey D, Ursic-Bedoya J, Meunier L. Drug-Induced hepatotoxicity. In: Schiff ER, editor. Schiff 's diseases of the liver. 12th Ed. New York: Wiley- Blackwell; 2018, pp. 740-73.

  10. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430-40.

  11. Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol 2012; 27: 1102-5.

  12. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248-55.

  13. Danan G, Teschke R. RUCAM in drug and herb-induced liver: the update. Int J Mol Sci 2015; 17,pii; E14. doi: 10.3390/ ijms17010014

  14. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  15. Teschke R, Frenzel C. Drug induced liver injury: Do we still need a routine liver biopsy for diagnosis today? Ann Hepatol 2014, 13: 121-7.

  16. Larrey D, Meunier L, Ursic-Bedoya J. Liver biopsy in chronic liver diseases: is there a favorable benefit: risk balance? Ann Hepatol 2017; 16: 487-9. doi: 10.5604/ 01.3001.0010.0272.

  17. Teschcke R, Schulze J, Eickhoff A, Danan G. Drug Induced Liver Injury: can biomarkers Assist RUCAM in causality Assessment? Int J Mol Sci 2017; 18: 803;doi:10.3390/ijms 18040803.

  18. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-64.

  19. 19 Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625-34.

  20. 20 Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, et al. International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology 2017; 152: 1078-89.




2020     |     www.medigraphic.com